Abstract

Simple SummaryWorldwide, there are more than 800,000 liver cancer patients each year, with more than 700,000 annual deaths. Chronic infection of hepatitis B virus (HBV) contributes to about 70% of the liver cancers. HBV-encoded regulatory protein hepatitis B virus X protein (HBx) is well known for its pleiotropic roles in oncogenesis, in part through promoting viral replication, as well as hijacking host signal transduction pathways. In this study, we observed that lysosomal components and its transcription factor EB (TFEB) were downregulated in hepatocellular carcinoma (HCC) patients. Here, we uncovered a potential mechanism showing HBx-induced oncogenesis may be mediated by downregulation of TFEB, leading to malignant dissemination.Hepatitis B virus (HBV) infection is a major etiological risk for the incidence of hepatocellular carcinoma (HCC), and HBV X protein (HBx) is essential for oncogenic transformation. It is not known that if HBx can sabotage the lysosomal system for transformation and tumorigenesis, or its mechanism if it does have an effect. Examining clinical data, we observed that the downregulation of lysosomal components and transcription factor EB (TFEB) was associated with a poor prognosis of HCC patients. In HCC cells, we found that expression of HBx suppressed TFEB, impaired biogenesis of autophagic-lysosome, and promoted cellular dissemination. HBx mediated downregulation of TFEB led to impairment of autophagic/lysosomal biogenesis and flux, and consequently, accumulation of integrin beta 1 (ITGB1) for motility of HCC cells. Conversely, TFEB, in a steady-state condition, through induction of lysosomal biogenesis restrained ITGB1 levels and limited mobility of HCC cells. Specifically, overexpression of TFEB upregulated and activated the cysteine proteases including cathepsin L (CTSL) to degrade ITGB1. Conversely, expression of cystatin A (CSTA) or cystatin B (CSTB), the cellular inhibitors of lysosomal cysteine proteinases, spared ITGB1 from degradation and promoted dissemination of HCC cells. Taken together, this study suggests a potential mechanism for HBV-mediated malignancy, showing that HBx mediated downregulation of TFEB leads to accumulation of ITGB1 for HCC cell migration.

Highlights

  • Liver cancer is the fourth leading cause of cancer-related death worldwide [1]

  • In hepatocellular carcinoma (HCC) cell lines, we demonstrated that HBV X protein (HBx) could downregulate transcription factor EB (TFEB) and impair lysosomal biogenesis and flux

  • As compared with the adjacent area, the expression of other auto-lysosomal components including lysosomal lipase (LIPA), lysosomal membrane component (LAPTM4A), as well as cathepsin S (CTSS) and cathepsin Z (CTSZ), was significantly decreased in the carcinoma area (Figure S1). These results suggest that the impeded lysosomal biogenesis is associated with the development and malignancy of liver cancer

Read more

Summary

Introduction

Liver cancer is the fourth leading cause of cancer-related death worldwide [1]. Hepatocellular carcinoma (HCC) comprises more than 90% of human liver cancers [2]. Risk factors for HCC include aflatoxin exposure, alcoholism, immune-related liver diseases, obesity, and viral infections with hepatitis B virus (HBV) or hepatitis C virus (HCV). Approximately 350 million people are chronically infected with HBV, and 20–30% of chronically HBV-infected individuals may develop cirrhosis and HCC [3]. About 70% of HCC cases are related to HBV infection in developing countries [4]. HBx can induce the genetic changes of tumor suppressor genes and oncogenes in liver cancer and can cause epigenetic aberrations [7,8]. The potential mechanism by which HBx promotes HCC development has not been fully elucidated

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call